Kenneth Anderson, MD

Kraft Family Professor of Medicine

Harvard Medical School

Dr. Anderson is the Kraft Family Professor of Medicine at Harvard Medical School as well as Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. He is a Doris Duke Distinguished Clinical Research Scientist and American Cancer Society Clinical Research Professor. After graduating from Johns Hopkins Medical School, he trained in internal medicine at John’s Hopkins Hospital, and then completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute. Over the last three decades, he has focused his laboratory and clinical research studies on multiple myeloma. He has developed laboratory and animal models of the tumor in it is microenvironment which have allowed for both identification of novel targets and validation of novel targeted therapies, and has then rapidly translated these studies to clinical trials culminating in FDA approval of novel targeted therapies. His paradigm for identifying and validating targets in the tumor cell and its milieu has transformed myeloma therapy and markedly improved patient outcome. He is the recipient of many scientific and humanitarian awards including the International Myeloma Workshop Waldenstrom’s Award in 2003, the International Myeloma Foundation Robert A. Kyle Lifetime Achievement Award in 2005, the American Association for Cancer Research Joseph H. Burchenal Award in 2007, and the American Society of Hematology William Dameshek Prize in 2008. He was elected into the Johns Hopkins Society of Scholars in 2009, the Institute of Medicine of the National Academy of Sciences in 2010, and the Royal College of Physicians and of Pathologists (UK) in 2010. In 2011 he received the American Society of Clinical Oncology David A. Karnofsky Award and the Hope Funds for Cancer Research Award of Excellence in Clinical Research, and in 2012 received the Ron Burton Humanitarian Award, the Harvard Medical School Warren Alpert Foundation Prize, and the American Cancer Society Medal of Honor.

Understanding the Fundamentals: Clonal Heterogeneity of Multiple Myeloma, Implications for Treatment of Relapsed/refractory Disease

The Evolving Landscape of Treatment Options for Relapsed/Refractory MM

James O. Armitage, MD

The Joe Shapiro Professor of Medicine

University of Nebraska Medical Center

Dr. James O. Armitage, a graduate of the University of Nebraska Medical Center, completed his internship and residency in internal medicine at Nebraska, a fellowship in hematology oncology at the University of Iowa and a brief stint in private practice in Omaha. He developed and directed the Bone Marrow Transplant program at the University of Iowa and later at the University of Nebraska. At Nebraska he served as Vice-Chair of Internal Medicine, Chief of the Section of Oncology and Hematology, Chair of the Department of Internal Medicine, and Dean of the College of Medicine. He currently is The Joe Shapiro Professor of Medicine at the University of Nebraska Medical Center. Dr. Armitage is board certified in internal medicine, medical oncology, and hematology, and a Fellow of both the American and Royal College of Physicians and of the American Association for the Advancement of Sciences. He has served on many national/international oncology committees including the United States National Cancer Advisory Board and the French National Cancer Advisory Board. He is past president of both the American Society of Clinical Oncology and the American Society of Blood and Marrow Transplantation. He has served on the Scientific Committee of the International Congress on Anti-Cancer Treatment in Paris, France, the International Symposium on Hodgkin Lymphoma in Cologne, Germany and the International Conference on Malignant Lymphoma in Lugano, Switzerland.

He has numerous honors including the Claude Jacquillat Award for achievement in Clinical Oncology from Paris, the San Salvatore Foundation Research Award from Lugano, Switzerland, the Richard and Hinda Rosenthal Foundation Award from the American Association of Cancer Research, the Heath Memorial Award from the University of Texas MD Anderson Cancer Center, the Robert A. Kyle Award from the Mayo Clinic, and election to the Association of American Physicians. Dr. Armitage has published more than 500 papers, written 110 chapters and is co-editor of 27 books. He and his wife, Nancy, have four children and ten grandchildren.

New Directions in the Management of Mantle Cell Lymphoma

Julie M. Vose, MD, MBA

Neumann M. and Mildred E. Harris Professor

University of Nebraska Medical Center

Julie M. Vose, MD is the Neumann M. and Mildred E. Harris Professor and Chief in the Division of Oncology/Hematology at the University of Nebraska Medical Center in Omaha, Nebraska. Dr Vose received her medical degree, completed her residency in Internal Medicine, served as Chief Resident, and completed a Fellowship in Hematology/Oncology at the University of Nebraska Medical Center. Dr Vose also completed a sabbatical at Stanford University. She also completed an MBA in Health Administration through the University of Colorado Business School.

Dr Vose has focused her career on translational research for improvement in the therapy of non-Hodgkin’s lymphoma (NHL) and Hodgkin lymphoma (HL) by developing a focused translational research program evaluating novel therapies such as radiolabeled monoclonal antibodies, idiotype vaccine therapies, pathway directed agents and stem cell transplantation. Dr Vose has been recognized for her NHL research on a national and international level through research awards and invited lectureships worldwide. In addition, her funding record and publications in NHL therapy and transplantation research have added substantially to the research and knowledge base for the therapy of lymphoma. She is currently the Co-Chair for the National Cancer Institute Lymphoma Sub-Committee, a member of the FDA Oncologic Drug Advisory Committee, and 2014-15 President elect for the American Society of Clinical Oncology (ASCO).

New Directions in the Management of Mantle Cell Lymphoma

Mark Socinski, MD

Professor of Medicine and Cardiothoracic Surgery

University of Pittsburgh Cancer Institute

Mark A. Socinski, MD, is a professor of medicine and cardiothoracic surgery at the University of Pittsburgh School of Medicine, and serves as director of the Lung Cancer Section at the University of Pittsburgh Cancer Institute, clinical associate director of the Lung SPORE, and co-director of UPMC Lung Cancer Center of Excellence, and co-director of the Lung and Thoracic Malignancies Program. Dr. Socinski specializes in all thoracic malignancies, including small cell and non-small cell lung cancers and mesothelioma. Dr. Socinski is board-certified in internal medicine and medical oncology. He received an undergraduate degree and a medical degree at the University of Vermont in Burlington, VT. He completed a residency in internal medicine at Harvard Medical School in Boston and a fellowship in medical oncology at Dana-Farber Cancer Institute in Boston. Dr. Socinski holds memberships in numerous professional societies such as the American College of Physicians, American Society of Clinical Oncology, International Association for the Study of Lung Cancer, and the American College of Chest Physicians. Dr. Socinski serves as co-Chair of the Thoracic Malignancies Steering Committee for the National Cancer Institute. Dr. Socinski’s primary research interests reside in all aspects of clinical trials related to the thoracic oncology population. He also serves on the Respiratory Core Committee of the Cancer and Leukemia Group B (Alliance) and has been instrumental in the development of many cooperative group trials.

Testing for Genetic Mutations in Advanced NSCLC

Clinical Challenges in the Personalized Treatment of Advanced NSCLC

Daniel J. George, MD

Associate Professor of Medicine

Duke University School of Medicine

Dr Daniel George is a tenured Associate Professor of Medicine and Surgery, Divisions of Medical Oncology and Urology in the Duke University School of Medicine. He also has appointments in the Duke Clinical Research Institute and the Duke Cancer Institute where he is the Director of Genitourinary (GU) Oncology. He an internationally recognized clinical researcher and thought leader in GU malignancies, with over 100 peer-reviewed publications. His areas of research include new drug development and biomarkers of GU cancers with an emphasis on signal transduction pathways and angiogenesis. Dr George is principal investigator of the Duke site for the Department of Defense (DOD) Prostate Cancer Clinical Trials Consortium since 2006, specializing in Phase I and II studies in prostate cancer. He is also the PI of the MaRCC registry in advanced renal cell carcinoma and Co-PI of the PCF 5000, an international, multi-sponsor supported registry in advanced prostate cancer.

Nationally, Dr George has served on the ASCO scientific committee from 2010-2012 and as the program chair of the GU committee in 2012. He currently serves on two grant committees for AACR. He is the scientific leader for kidney cancer in the Alliance Cooperative Group since 2011 and serves on the Alliance GU scientific committee, NCI GU Steering Committee and the NCI Renal Task Force. He also serves as a senior editor for Clinical Cancer Research, Clinical Advances in Hematology and Oncology, and Prostate Cancer and Prostatic Diseases.

Selecting and Sequencing Therapies for Advanced Prostate Cancer

New Directions in the Management of Advanced Prostate Cancer

Michael R. Harrison, MD

Assistant Professor of Medicine

Duke University School of Medicine

Patrick F. Fogarty, MD

Assistant Professor of Medicine at the Hospital of the University of Pennsylvania

Perelman School of Medicine, University of Pennsylvania

Manish A. Shah, MD

Director, Gastrointestinal Oncology

Weill Cornell Medical College

Dr. Manish A. Shah completed his undergraduate education at Johns Hopkins University in 1991, going on to receive his Medical Degree from Harvard Medical School/MIT Health Sciences and Technology program in 1996, graduating Magna Cum Laude. He completed his Internal Medicine Residency training at Duke University Medical Center in 1999, and his Fellowship at Memorial Sloan-Kettering Cancer Center in 2001, where he served as Chief Oncology Fellow. Dr. Shah was recruited from Memorial Sloan-Kettering Cancer Center in order to serve as Director of the Gastrointestinal Oncology Program within the Division of Hematology and Medical Oncology and the Center for Advanced Digestive Care at Weill Cornell Medical College/ NewYork-Presbyterian Hospital. Dr. Shah is the recipient of several awards including the American Society of Clinical Oncology’s Young Investigator and Career Development Awards, as well as the Journal for Surgical Oncology’s Donald L. Morton Award. Most recently, Dr. Shah was the recipient of the Bartlett Family Associate Professor for Gastrointestinal Oncology award. Dr. Shah is a distinguished peer-review funded investigator and has led several Phase I, II and III clinical trials in GI malignancies. His areas of translational research interests focus on improving the understanding of upper GI cancers, hereditary GI malignancies, genomic evaluations of malignancy, and the effects of the external environment on the genetic causes of malignancy.

In addition to his research pursuits, Dr. Shah is involved in several extramural professional responsibilities. Dr. Shah is a member of the American Society of Clinical Oncology (ASCO) and the American Association for Clinical Research (AACR). He has authored several books, including Dx/Rx: Upper Gastrointestinal Malignancies: Cancers of the Stomach and Esophagus, as well as 100 Questions and Answers about Stomach Cancer. Dr. Shah is the Editor for The Management of Complex Cases in Gastrointestinal Oncology Case Series for the Journal of Gastrointestinal Oncology and the Series Editor for the Dx/RX: Oncology Series published by Jones and Bartlett Publishers. In addition, Dr. Shah serves on the Editorial Board of the Journal of Clinical Oncology, and as a reviewer for several high-impact journals, including Journal of the American Medical Association, PLOS One, and Lancet Oncology. Additionally, Dr. Shah serves as Chair of the Scientific Advisory Board for the DeGregorio Family Foundation for Stomach and Esophageal Cancer Education and Research, and Vice Chair of the National Cancer Institute’s Gastroesophageal Task Force.

Personalizing the Management of Advanced Gastric Cancer

Watch Connect online with thousands of your peers.
Connect Engage in real-time Q&A with top factuly.
Choose Learn about the latest treatment options.
Connect Earn AMA PRA
Category 1 Credits